Research

New COVID-19 nasal spray outperforms current antibody treatments in mice

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19.

Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus' ability to enter cells.

Fighting viruses is as easy as breathing

The average person will take more than 600 million breaths over the course of their life. Every breath stretches the lungs’ tissues with each inhale and relaxes them with each exhale. The mere motions of breathing are known to influence vital functions of the lungs, including their development in babies, the production of air-exchange-enhancing fluid on their inner surfaces, and maintenance of healthy tissue structure.

Novartis announces new organizational structure

Novartis announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.

Cancer repair mechanism could be potential drug target

While cancer therapies targeting specific genes or disease pathways have extended lives, they can also lead to highly resistant tumors when small reservoirs of cancer cells survive treatment, grow, and spread.

Searching for ways to extend the survival benefit of targeted therapies, a team led by researchers at the Duke Cancer Institute identified a potential new tactic to disrupt the repair mechanism that cancer cells use after treatment, blunting their ability to regenerate.

Aspirin may reduce death In hospitalized COVID-19 patients

Researchers at the George Washington University published findings from the world's largest cohort study showing that hospitalized patients with moderate COVID-19 who were given aspirin early on in their treatment had a lower risk of dying compared to patients who were not given aspirin.

Chemical found in leafy greens shown to slow growth of COVID-19 and common cold viruses

Researchers at Johns Hopkins Children’s Center report evidence from lab experiments that a chemical derived from a compound found abundantly in broccoli and other cruciferous plants may offer a potentially new and potent weapon against the viruses that cause COVID-19 and the common cold. COVID-19 has already killed more than 6 million people worldwide, and studies have shown that common colds cost an estimated economic loss of $25 billion in the U.S. alone each year.

COVID-19 Increases risk of type 2 diabetes

People who have had COVID-19 are at increased risk of developing type 2 diabetes. This is the result of a study by DDZ, DZD and IQVIA, which has now been published in Diabetologia.

Studies show that the human pancreas can also be a target of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2 virus).

Research & Development

New COVID-19 nasal spray outperforms current antibody treatments in mice

Fighting viruses is as easy as breathing

Novartis announces new organizational structure

Cancer repair mechanism could be potential drug target

Aspirin may reduce death In hospitalized COVID-19 patients

Chemical found in leafy greens shown to slow growth of COVID-19 and common cold viruses

COVID-19 Increases risk of type 2 diabetes

More Pharma News ...